Notice of the enrollment of the first patient in the Japanese Phase III clinical trial of the achondroplasia treatment umedaptanib pegol

Worth reading

29Immaterial

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Improvement

Direction inferred from the company’s description.

Scale

—

Displayed only when the document provides numerical figures.

Wording

Conditional

How definitive the wording is.

First Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Achondroplasia Treatment umedaptanib pegol

Subject Entity

RIBOMIC Inc. (filing company)

Target Locations / Products

umedaptanib pegol (RBM-007), and a domestic Phase 3 clinical trial targeting pediatric patients with achondroplasia aged 2 to 14

This disclosure07/02/2026

Amount of Impact on Business Performance

No amount is specified (there will be no impact on full-year results for the fiscal year ending March 2027)

Impact on Earnings Forecast

There will be no impact on full-year earnings for the fiscal year ending March 2027

Outlook

RIBOMIC Inc. will accelerate patient enrollment at multiple sites in Japan, proceed with evaluating the treatment's clinical value, and further advance efforts toward the development of pharmaceuticals originating in Japan.

Event that occurred
Item	Details
Event name	First Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Achondroplasia Treatment umedaptanib pegol
Subject Entity	RIBOMIC Inc. (filing company)
Target Locations / Products	umedaptanib pegol (RBM-007), and a domestic Phase 3 clinical trial targeting pediatric patients with achondroplasia aged 2 to 14
Amount of Impact on Business Performance	No amount is specified (there will be no impact on full-year results for the fiscal year ending March 2027)
Impact on Earnings Forecast	There will be no impact on full-year earnings for the fiscal year ending March 2027
Outlook	RIBOMIC Inc. will accelerate patient enrollment at multiple sites in Japan, proceed with evaluating the treatment's clinical value, and further advance efforts toward the development of pharmaceuticals originating in Japan.

Items this document does not state (19)

Date of occurrenceDate recognized / date notice receivedCauseAccounting period in which recognizedType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The enrollment of the first patient is considered an important milestone demonstrating steady progress in the development pipeline. RIBOMIC Inc. will accelerate patient enrollment at multiple sites in Japan and proceed with evaluating the treatment's clinical value.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.

Notice of the enrollment of the first patient in the Japanese Phase III clinical trial of the achondroplasia treatment ume­daptanib pegol

First Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Achondroplasia Treatment umedaptanib pegol

The reasons the company gives

How to read this page